Amendment to Schedule 13D Filing for Arcellx, Inc.

This filing is an amendment to a previous Schedule 13D filing concerning Arcellx, Inc. The amendment details a merger agreement entered into by Arcellx, Inc. with Gilead Sciences, Inc. and its subsidiary Ravens Sub, Inc. The agreement involves a tender offer for Arcellx common stock at $115.00 per share, plus a contingent value right of $5.00 per share, to be followed by a merger. New Enterprise Associates 15, L.P. (NEA 15) and associated entities, as reporting persons, have entered into tender and support agreements with Gilead Sciences, Inc. NEA 15 currently holds 3,045,262 shares of Arcellx common stock, representing 5.3% ownership. The filing also includes exhibits detailing the agreement for joint filing and a power of attorney authorizing the filing by representatives.